April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Heterogeneous Intraocular Pressure (IOP) Response After Topical Administration of Trusopt or Xalatan in Ocular Normotensive Conscious Cynomolgus Monkeys
Author Affiliations & Notes
  • T. T. Lam
    Toxicology, Covance Laboratories, Madison, Wisconsin
  • C. Busse
    Toxicology, Covance Laboratories, Madison, Wisconsin
  • J. Boehme
    Toxicology, Covance Laboratories, Madison, Wisconsin
  • W. K. McVicar
    Inotek Pharmaceuticals Corporation, Lexington, Massachusetts
  • N. Kim
    Inotek Pharmaceuticals Corporation, Lexington, Massachusetts
  • T. McCauley
    Inotek Pharmaceuticals Corporation, Lexington, Massachusetts
  • B. J. Christian
    Toxicology, Covance Laboratories, Madison, Wisconsin
  • Footnotes
    Commercial Relationships  T.T. Lam, Inotek Pharmaceuticals Corporation, F; C. Busse, Inotek Pharmaceuticals Corporation, F; J. Boehme, Inotek Pharmaceuticals Corporation, F; W.K. McVicar, None; N. Kim, None; T. McCauley, None; B.J. Christian, Inotek Pharmaceuticals Corporation, F.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 564. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. T. Lam, C. Busse, J. Boehme, W. K. McVicar, N. Kim, T. McCauley, B. J. Christian; Heterogeneous Intraocular Pressure (IOP) Response After Topical Administration of Trusopt or Xalatan in Ocular Normotensive Conscious Cynomolgus Monkeys. Invest. Ophthalmol. Vis. Sci. 2010;51(13):564.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To evaluate the heterogeneity and relationship of IOP-lowering response of two agents with different mechanisms of action, Trusopt, and Xalatan, in ocular normotensive conscious cynomolgus monkeys

 
Methods:
 

Trusopt (2%), a carbonic anhydrase inhibitor (CAI), or Xalatan (0.005%), a prostanoid selective FP receptor agonist (PG), was applied to the right eyes of 10 ocular normotensive cynomolgus monkeys; the corresponding vehicles were applied to the left eyes. IOPs were measured in conscious animals with a pneumatonometer (Mentor Classic II) pre-dose, 2, 4, 6, 8, and up to 24 hours (mean of 3 readings per time point). Maximal IOP changes were calculated as percentages relative to predose values and relative to the left/control eye of each animal. The coefficient of correlation was calculated based on linear regression of the maximal IOP changes in response to the agents.

 
Results:
 

The following tables summarize the IOP changes and their distribution of the normotensive monkeys following topical administration of Trusopt and Xalatan.For individual animals, there was no correlation of the magnitude of IOP reduction between the two agents.

 
Conclusions:
 

In ocular normotensive monkeys, the magnitude of IOP response to two IOP lowering agents with different modes of action (CAI, PG) is heterogeneous and shows no correlation for individual animals.  

 
Keywords: intraocular pressure • aqueous • outflow: trabecular meshwork 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×